Funding

#Amplify Therapeutics #BioInnovation Institute #Funding #Fuse Vectors #Metsystem #Parkinson's

Three companies join the BioInnovation Institute programme  

BioInnovation Institute (BII), life science incubator, has announced the addition of six companies who will receive additional financial support through its Venture House programme, created to further support former Venture Lab companies through their next phase of growth. Three of these are key to the advancement of gene therapies,… Read More

#News

#Alamar Biosciences #Financing #Funding #Investment #Proteomics

Proteomics company raises $128 Million in Series C financing

Proteomics company Alamar Biosciences closed $100 million in Series C financing with the second close of an additional $28 million expected to happen within the next 30 days. This new capital brings Alamar's total funding to date to nearly $250 million. The financing round was led by Sands Capital and… Read More

#Business & Investment #News

GBP pound sterling funding
#CatSci #Funding #Oligonucleotides #RNA sequencing #Wales

CatSci wins Welsh grant for oligonucleotides development

CatSci has won a Welsh Government SMART Capital Equipment Fund grant to enhance its oligonucleotides capability. The grant will enable the company to invest in new equipment that will increase the rapid creation of a large pool of candidates of RNA/DNA sequences. Production of oligonucleotides is currently both slow and… Read More

#Business & Investment #News

GBP pound sterling funding
#Alentis Therapeutics #Curve Therapeutics #Drug discovery #Finance #Funding #Pfizer Ventures #Seed funding #Solid tumours

£40.5 million invested in discovery platform and to advance pipeline 

Curve Therapeutics, a company developing an intracellular screening platform to address disease targets, has completed a £40.5 million ($51.37 million) Series A financing round. Pfizer Ventures led the round with participation from Columbus Venture Partners and British Patient Capital, which join founding investor Advent Life Sciences and… Read More

#News

2024 predictions, road forward
#2024 predictions #Funding #Investment #Life science #Pharma Collective #Treehill Partners

2024 predictions: Thought leaders on finance and investment 

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes, which include insight into the future for cancer and immunotherapy, as well as AI, ML and automation. Read More

#Exclusive Content #Trends & Analysis

#Artificial intelligence (AI) #Drug discovery #Funding #Ginkgo #Immunology / Virology & Vaccines #Machine learning #Vaccine adjuvants

Ginkgo Bioworks to discover and develop novel vaccine adjuvants 

A five-year contract totalling up to $31 million including programme options has been awarded to Ginkgo Bioworks to discover and develop next-generation vaccine adjuvants. The contract was awarded by the Defense Threat Reduction Agency’s (DTRA) Joint Science and Technology Office (JSTO) for the Chemical and Biological Defense (CBD)… Read More

#News

Bill & Melinda Gates Foundation
#Bill & Melinda Gates Foundation #Drug development #Drug discovery #Finance #Funding #Mouse models #PhaSER Biomedical (PhaSER)

$2.3m Gates Foundation grant to accelerate global drug discovery 

Edinburgh-based PhaSER Biomedical (PhaSER) has received a Bill & Melinda Gates Foundation grant totalling $2.3m to continue its work in accelerating drug discovery and development.   PhaSER will provide 8HUM transgenic mouse models, humanised for key pathways involved in the metabolism and disposition of drugs, to all the… Read More

#News

#Collaboration #Dermatology #Finance #Funding #Immuno-dermatology #Medicxi

$100M financing to advance immuno-dermatology pipeline 

Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. The company originates from the aggregation of six Medicxi companies.  Co-founded by Medicxi and several dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School… Read More

#Business & Investment #News

Bacteria
#Aston University #Drug discovery #Funding #Microbiology #University of Warwick

UK university partnership wins £1.8m for drug discovery research

A team from Aston University and the University of Warwick has secured a £1.8 ($2.2) million grant to engineer microbial cell factories to produce membrane proteins which will support future drug screening and sustainable chemical production. The Engineering Biology Mission Award was given by UK Research… Read More

#News

Cancer cells
#Funding #Immunotherpy #NeoPhore #Proteins #Small molecules

Financing extension for neoantigen immuno-oncology company 

NeoPhore has announced a further extension of £9.6 million (approximately $12.2 million) to its Series B financing round, bringing the total raised to £31.1 million (approximately $39.5 million).  The company is building a pipeline of small molecule drugs targeting novel proteins across the DNA mismatch repair (MMR) pathway to generate… Read More

#Business & Investment #Cancer Research #News

#Clinical trial design #Dementia #Funding #Neurodegenerative disorders #University College London

UK dementia research gets £49.9 million funding boost

Head of clinical trials at the University College London (UCL) Dementia Research Centre, Dr Cath Mummery, has been announced as the Director of a new network of dementia trial sites across the country. The UK government has authorised £49.9 ($63.4) million of new funding to improve… Read More

#Editor's Choice #News

Neuroscience
#Cerebrotendinous xanthomatosis #Funding #Gene therapy #Neurodegenerative disorders #Neuroscience #Vivet Therapeutics

Funds advance gene therapy for cerebrotendinous xanthomatosis 

Vivet Therapeutics has received €4.9 million from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.   This funding is from the “Innovations in biotherapies” framework of the France Health Innovation Plan 2030 and specifically the acceleration strategy… Read More

#Business & Investment #News

#Arxx Therapeutic #Calluna Pharma #Funding #Immune system #Monoclonal antibodies #Oxitope Pharm #Therapeutic Antibodies

Calluna Pharma announces €75 million Series A financing 

Oxitope Pharma and Arxx Therapeutics, companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, has announced their merger to form Calluna Pharma.   Calluna has raised €75 million in a series A financing and is backed by Oxitope and Arxx’s existing… Read More

#Business & Investment #News

Genesis 2024
#Biodollar #Business #Comment #Funding #Genesis 2023 #Innovation #Life science

Comment: Reflections from Genesis 2023 

The annual Genesis conference took place at the end of 2023 in London, bringing together key opinion leaders, investors and innovators from across the life sciences sector to exchange insights, debate trends and generate deals. DDW’s Megan Thomas attended and reflects on highlights of the programme.  Stacking the deck of… Read More

#Business & Investment #Exclusive Content #Opinion

Precision medicine
#Drug discovery #Funding #Precision medicine #Sano Genetics #Software

$11.4m raised to power a ‘precision medicine revolution’  

Sano Genetics, a software company working to accelerate precision medicine research, has raised $11.4 million in new funding, led by Plural with participation from existing investors including MMC Ventures, Episode 1 and Seedcamp.   Sano Genetics is developing software which combines genetic testing, recruitment, and long-term engagement in one platform, accelerating… Read More

#Business & Investment #News

Market growth 2024
#Biotech #Funding #GlobalData #Investment #Market reporting

Biotech funding recovery predicted for 2024

The biotech market is heading to recovery in 2024, following a marked downturn in investment in 2022 and 2023, according to healthcare industry professionals. A GlobalData survey ‘The State of the Biopharmaceutical Industry 2024’ found that more than 40% of the healthcare industry professionals surveyed globally expressed an optimistic or… Read More

#Business & Investment #News #Trending News